ReshmaRangwalaMD
Internal Medicine • Saint Louis, MOHospital Medicine/Hospitalist, Hematology/Oncology
Physician
Are you Dr. Rangwala?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
Saint Louis, MO 63110Phone+1 314-362-1700Fax+1 314-362-9878
Summary
- Dr. Reshma Rangwala, MD is an internist in Saint Louis, Missouri. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
University of Cincinnati College of MedicineClass of 2006
Certifications & Licensure
PA State Medical License 2010 - 2016
Publications & Presentations
PubMed
- 55 citationsErbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between Merlin and adherens junction protein complexes in Schwa...Reshma Rangwala, Fatima Banine, Jean-Paul Borg, Larry S. Sherman
The Journal of Biological Chemistry. 2005-03-25 - 282 citationsPhase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanomaReshma Rangwala, Robert D. Leone, Yunyoung C. Chang, Leslie A. Fecher, Lynn M. Schuchter
Autophagy. 2014-05-20 - 285 citationsCombined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.Dan T. Vogl, Edward A. Stadtmauer, Kay See Tan, Daniel F. Heitjan, Lisa E. Davis
Autophagy. 2014-05-20
Press Mentions
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31st, 2024- Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDSMay 3rd, 2023
- Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 ObjectivesJanuary 9th, 2023
- Join now to see all
